Document is current
Any future updates will be listed below
-
Authors
Burgers, Femke H. https://orcid.org/0000-0002-7279-9216
van der Mijn, Johannes C. K.
Seijkens, Tom T. P.
Jedema, Inge
Bex, Axel
Haanen, John B. A. G. https://orcid.org/0000-0001-5884-7704
- License Information
-
More Information
Article History
Accepted: 20 June 2025
First Online: 22 July 2025
Competing interests
: J.C.K.M. receives research funding from Bayer B.V. and received financial compensation for consultancy services for AstraZeneca, Merck/MSD and Ipsen. A.B. received an educational restricted grant from Pfizer for a neoadjuvant trial, holds membership on the steering committee of adjuvant trials from Roche and BMS and is on the advisory board for Ipsen. J.B.A.G.H. received compensation for advisory roles for Achilles Therapeutics, AZ, BioNTech, BMS, CureVac, Eisai, Gadeta, Imcyse, Immunocore, Instil Bio, Iovance Biotherapeutics, Ipsen, MSD, Merck Serono, Molecular Partners, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Scenic, Third Rock Ventures and T-knife, and has received grants (all paid to the Institute) from Amgen, Asher Bio, BioNTech, BMS, MSD, Novartis, Neogene Therapeutics and Sastra Cell Therapy. The other authors declare no competing interests.
